专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

HRP940824B1 HYBRID CELL LINE FOR PRODUCING MONOCLONAL ANTIBODY TO A HUMAN PROTHYMOCYTE ANTIGEN, ANTIBODY, AND METHODS 未知
公开(公告)号：HRP940824B1
公开(公告)日：1999-12-31
申请号：HRP940824
申请日：1994-10-26
申请人： GIDEON GOLDSTEIN
发明人： GOLDSTEIN GIDEON
IPC分类号： A61K39/395 , C12N5/00 , C12N15/00 , C12P1/00 , C12P21/00 , C12R1/91 , G01N33/50

2. 发明专利

HRP940808B1 HYBRID CELL LINE FOR PRODUCING MONOCLONAL ANTIBODY TO HELPER T CELLS, ANTIBODY AND METHOD OF PREPARATION THEREOF 未知
公开(公告)号：HRP940808B1
公开(公告)日：1999-12-31
申请号：HRP940808
申请日：1994-10-26
申请人： GIDEON GOLDSTEIN
发明人： GOLDSTEIN GIDEON
IPC分类号： A61K39/395 , C12N5/00 , C12N15/00 , C12P1/00 , C12P21/00 , G01N33/50

3. 发明专利

HRP940809B1 HYBRID CELL LINE FOR PRODUCING COMPLEMENT-FIXING MONOCLONAL ANTIBODY TO HUMAN T CELLS, ANTIBODY AND METHODS 未知
公开(公告)号：HRP940809B1
公开(公告)日：1999-10-31
申请号：HRP940809
申请日：1994-10-26
申请人： GIDEON GOLDSTEIN
发明人： GOLDSTEIN GIDEON
IPC分类号： A61K31/395 , A61K39/395 , C12N5/00 , C12N15/00 , C12P1/00 , C12R1/91 , G01N33/50

4. 发明专利

AU701223B2 Method of measuring thymopoietin proteins in plasma and serum 未知
公开(公告)号：AU701223B2
公开(公告)日：1999-01-21
申请号：AU3718495
申请日：1995-09-18
申请人： GIDEON GOLDSTEIN
发明人： GOLDSTEIN GIDEON , CULLER MICHAEL D
IPC分类号： C07K14/66 , G01N33/74 , C07K14/00 , G01N33/53 , G01N33/537 , G01N33/543
摘要： Method for accurately measuring thymopoietin (TP) in human serum or plasma by dissociating TP from protein complexes, releasing bound TP in a unbound form, extracting TP, preparing it for assay, and measuring TP levels in a suitable assay.

5. 发明专利

HRP940786B1 HYBRID CELL LINE FOR PRODUCTION OF MONOCLONAL ANTIBODY FOR HUMAN CYTOTOXIC AND SUPRESSOR T CELLS, ANTIBODY AND PROCESS 未知
公开(公告)号：HRP940786B1
公开(公告)日：1999-12-31
申请号：HRP940786
申请日：1994-10-26
申请人： GIDEON GOLDSTEIN
发明人： GOLDSTEIN GIDEON
IPC分类号： A61K39/395 , C12N5/00 , C12N15/00 , C12P1/00 , C12R1/91 , G01N33/50

6. 发明专利

HRP940809A2 HYBRID CELL LINE FOR PRODUCING COMPLEMENT-FIXING MONOCLONAL ANTIBODY TO HUMAN T CELLS, ANTIBODY AND METHODS 未知
公开(公告)号：HRP940809A2
公开(公告)日：1997-12-31
申请号：HRP940809
申请日：1994-10-26
申请人： GIDEON GOLDSTEIN
发明人： GOLDSTEIN GIDEON
IPC分类号： A61K31/395 , A61K39/395 , C12N5/00 , C12N15/00 , C12P1/00 , C12R1/91 , G01N33/50

7. 发明专利

AU682898B2 Novel tripeptides useful in immune and CNS therapy 未知
公开(公告)号：AU682898B2
公开(公告)日：1997-10-23
申请号：AU7868194
申请日：1994-08-17
申请人： GIDEON GOLDSTEIN
发明人： GOLDSTEIN GIDEON , SHENBAGAMURTHI PONNIAH , KOENIG JAMES I
IPC分类号： G01N33/50 , A61K38/00 , A61P25/24 , A61P25/26 , A61P37/00 , C07K5/072 , C07K5/09 , C07K5/097 , C07K5/00 , C07K7/00 , C07K17/00
摘要： Tripeptides capable of regulating the function of cells of the mammalian immune and/or central nervous system, pharmaceutical compositions containing the peptides and methods of use thereof are provided.

8. 发明申请

US20090092626A1 Compositions and methods for the treatment and prophylaxis of multiple strains and subtypes of HIV-1 失效
标题翻译：用于治疗和预防HIV-1多重菌株和亚型的组合物和方法
公开(公告)号：US20090092626A1
公开(公告)日：2009-04-09
申请号：US11891893
申请日：2007-08-14
申请人： Gideon Goldstein
发明人： Gideon Goldstein
IPC分类号： A61K39/00
CPC分类号： A61K39/21 , A61K39/12 , A61K39/385 , A61K39/39 , A61K2039/54 , A61K2039/545 , A61K2039/55511 , A61K2039/6018 , C12N2740/16334
摘要： A self-adjuvanting immunogenic composition comprising multiple immunogens, each immunogen comprising a lipopeptide cap, a universal T helper sequence and an immunodominant HIV-1 Tat B cell epitope. The immunogen also comprises one or more linker sequences and/or polar charged amino acid sequences. The HIV-1 Tat B cell epitope of each immunogen has an amino acid sequence of V-D-P-Xaa7-L-Xaa9-P-W-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-amide SEQ ID NO: 1, in which the amino acid positions at Xaa7, Xaa9 and Xaa12 are selected from specific amino acid residues choices and in which the amino acid positions at Xaa13-Xaa16 may be absent or specific amino acid residue choices. The lipopeptide is a dipalmitoyl-S-glyceryl-cysteine or a tripalmitoyl-S-glyceryl cysteine or N-acetyl (dipalmitoyl-S-glyceryl cysteine), each with an optional neutral amino acid linker. Optional polar sequences of at least four charged polar amino acids enhance solubility of the immunogen and are located at the carboxy terminal end of the lipopeptide cap, optionally flanked by neutral linker amino acids, or elsewhere in the immunogen. In the composition, each immunogen differs from another immunogen by an amino acid variation at amino acid position Xaa7, Xaa9 or Xaa12 of the immunodominant HIV-1 Tat epitope. Such compositions can induce anti-HIV-1 Tat antibodies with geometric mean titers of greater than 1,000,000 on multiple HIV-1 Tat variants, when employed to immunize a subject, without any extrinsic adjuvant.
摘要翻译：包含多种免疫原的自佐剂免疫原性组合物，每种免疫原包含脂肽帽，通用T辅助序列和免疫显性HIV-1 TatB细胞表位。免疫原还包含一个或多个接头序列和/或极性带电荷的氨基酸序列。每种免疫原的HIV-1 Tat B细胞表位具有VDP-Xaa7-L-Xaa9-PW-Xaa12-Xaa13-Xaa14-Xaa15-Xaa16-酰胺SEQ ID NO：1的氨基酸序列，其中氨基酸位置在Xaa7中，Xaa9和Xaa12选自特定的氨基酸残基选择，其中Xaa13-Xaa16的氨基酸位置可能不存在或特定的氨基酸残基选择。脂肽是二棕榈酰基-S-甘油基半胱氨酸或三棕榈酰基-S-甘油基半胱氨酸或N-乙酰基（二棕榈酰基-S-甘油基半胱氨酸），每个具有任选的中性氨基酸接头。至少四个带电荷的极性氨基酸的任选的极性序列增强了免疫原的溶解度，并且位于脂肽帽的羧基末端，任选侧接中性接头氨基酸或免疫原中的其他位置。在组合物中，每个免疫原通过免疫显性HIV-1 Tat表位的氨基酸位置Xaa7，Xaa9或Xaa12处的氨基酸变化与另一种免疫原不同。当用于免疫受试者时，这些组合物可以在多种HIV-1 Tat变体上诱导具有大于1,000,000的几何平均滴度的抗HIV-1 Tat抗体，而没有任何外源性佐剂。

9. 发明授权

US07008622B2 Methods and compositions for impairing multiplication of HIV-1 失效
公开(公告)号：US07008622B2
公开(公告)日：2006-03-07
申请号：US10086208
申请日：2002-02-28
申请人： Gideon Goldstein
发明人： Gideon Goldstein
IPC分类号： A61K39/42
CPC分类号： C07K14/005 , A61K38/10 , A61K39/00 , A61K39/12 , A61K39/21 , A61K2039/545 , A61K2039/55566 , A61K2039/6037 , C07K16/1072 , C07K2317/34 , C07K2319/60 , C12N2740/15022 , C12N2740/16322 , C12N2740/16334
摘要： A composition which elicits antibodies to greater than 95%, and even greater than 99%, of the known variants of HIV-1 Tat protein contains at least one peptide or polypeptide of the formula of Epitope I (based on amino acids 2-10 of HIV-1 Tat consensus sequence) and optionally one or more of a peptide or polypeptide of Epitope II (based on amino acids 41 to 51 of that sequence), of Epitope III (based on amino acids 52-62 of that sequence), or of Epitope IV (based on amino acids 62 through 72 of that sequence with a C-terminal Pro). Vaccinal and pharmaceutical compositions can contain the antibodies induced by the peptide compositions for use in passive therapy. Diagnostic compositions and uses are described for assessing the immune status of vaccinated patients.

10. 发明申请

US20050245454A1 Methods and compositions for impairing multiplication of HIV-1 审中-公开
标题翻译：减少HIV-1增殖的方法和组合物
公开(公告)号：US20050245454A1
公开(公告)日：2005-11-03
申请号：US11176868
申请日：2005-07-08
申请人： Gideon Goldstein
发明人： Gideon Goldstein
IPC分类号： G01N33/50 , A61K35/76 , A61K38/00 , A61K38/08 , A61K38/10 , A61K39/00 , A61K39/395 , A61K48/00 , A61P31/18 , C07K7/06 , C07K7/08 , C07K14/00 , C07K14/16 , C07K16/08 , C07K16/10 , C07K19/00 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/09 , C12P21/08 , G01N33/15 , G01N33/53 , G01N33/566 , G01N33/569
CPC分类号： C07K14/005 , A61K38/08 , A61K39/00 , A61K2039/505 , A61K2039/6037 , A61K2039/6043 , C07K7/06 , C07K16/1045 , C07K16/1072 , C07K2317/21 , C07K2317/34 , C12N2740/16322 , G01N33/56988 , G01N2333/163 , G01N2469/20
摘要： A composition which elicits antibodies to multiple known variants of Tat protein of HIV-1 of both the B and non-B clades contains the peptide R1-Asp-Pro-Asn-Leu-Asp-Pro-Trp-Asn-R2 SEQ ID NO: 23, and preferably an additional at least two variants of a peptide or polypeptide of the formula: R1-Asp-Pro-Y7-Leu-X9-Pro-Trp-Z12-R2 (SEQ ID NO: 8). In this composition, at least one of the two variants contains Arg at Y7 and Lys at Z12, and in at least a second of the two variants Y7 is Asn and Z12 is Asn. Vaccinal and pharmaceutical compositions can contain one or more such peptides associated with carrier proteins, associated in multiple antigenic peptides or as part of recombinant proteins. Diagnostic compositions and uses are described for assessing the immune status of vaccinated patients.
摘要翻译：对B和非B进化枝的HIV-1的多种已知Tat蛋白变体产生抗体的组合物包含肽R1-Asp-Pro-Asn-Leu-Asp-Pro-Trp-Asn-R2 SEQ ID NO ：23，并且优选另外至少两种下式的肽或多肽的变体：R1-Asp-Pro-Y7-N-N-N-Pro- Trp-Z 12-R2（SEQ ID NO：8）。在该组合物中，两种变体中的至少一种在Y 7中含有Arg，在Z 12上含有Lys，并且在两种变体Y 2中的至少一个中， 7是Asn，Z 12是Asn。疫苗和药物组合物可以含有与多种抗原肽相关的载体蛋白相关的一种或多种这样的肽，或作为重组蛋白的一部分。描述了用于评估接种的患者的免疫状态的诊断组合物和用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式